These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20520650)

  • 21. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
    Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
    Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
    Persano L; Pistollato F; Rampazzo E; Della Puppa A; Abbadi S; Frasson C; Volpin F; Indraccolo S; Scienza R; Basso G
    Cell Death Dis; 2012 Oct; 3(10):e412. PubMed ID: 23076220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
    Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
    J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
    Jiang G; Li LT; Xin Y; Zhang L; Liu YQ; Zheng JN
    Curr Med Chem; 2012; 19(23):3886-92. PubMed ID: 22788764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
    Balaña C; Ramirez JL; Taron M; Roussos Y; Ariza A; Ballester R; Sarries C; Mendez P; Sanchez JJ; Rosell R
    Clin Cancer Res; 2003 Apr; 9(4):1461-8. PubMed ID: 12684420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional control of O
    Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
    J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
    Xiao S; Yang Z; Qiu X; Lv R; Liu J; Wu M; Liao Y; Liu Q
    Oncotarget; 2016 Aug; 7(31):50229-50238. PubMed ID: 27384876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
    Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
    Rahman MA; Gras Navarro A; Brekke J; Engelsen A; Bindesbøll C; Sarowar S; Bahador M; Bifulco E; Goplen D; Waha A; Lie SA; Gjertsen BT; Selheim F; Enger PØ; Simonsen A; Chekenya M
    Br J Cancer; 2019 Oct; 121(7):545-555. PubMed ID: 31413318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
    Xu H; Zhang Y; Li L; Ren Y; Qian F; Wang L; Ma H; Quan A; Liu H; Yu R
    Drug Deliv; 2023 Dec; 30(1):1-13. PubMed ID: 36579448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
    Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
    Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
    Chalmers AJ; Ruff EM; Martindale C; Lovegrove N; Short SC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1511-9. PubMed ID: 19931733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
    Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
    Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.